What Does the FDA's 2026 Proposal to Exclude Semaglutide, Tirzepatide, and Liraglutide From the 503B Bulks List Mean for Clinics Sourcing Compounded GLP-1s?

As of August 2026, the FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound these substances from bulk drug substances when FDA-approved versions are available. The comment period closed July 30, 2026; a final determination remains pending.

This proposal primarily constrains 503B bulk pathways outside of shortage listings. It does not eliminate patient-specific 503A compounding, though "essentially a copy" limitations continue to apply under section 503A of the FD&C Act. Here is what clinic operators need to understand right now.

On April 30, 2026, the FDA announced a proposal not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List. As of mid-August 2026, no final determination has been issued — but the comment period closed July 30, 2026, and a final rule is pending. Clinics should treat the current period as one of heightened documentation and verification requirements, not a return to pre-2025 operating conditions.

The proposal was published in the Federal Register on May 1, 2026 (91 FR 23431). After reviewing nominations, the FDA determined there was insufficient evidence of clinical need for outsourcing facilities to compound these drugs from bulk substances. The public comment period, originally set to close June 29–30 and later extended, ended July 30, 2026.

Under section 503B of the Federal Food, Drug, and Cosmetic Act, outsourcing facilities generally may compound using bulk drug substances only if:

• The substance appears on the 503B Bulks List, or
• The finished drug is on the FDA drug shortage list at the time of compounding, distribution, and dispensing

Semaglutide and tirzepatide shortages were resolved in 2025 and 2024, respectively. Liraglutide's shortage status has varied — practitioners must verify the current FDA shortage database for any given date. The proposal, if finalized, would formalize the exclusion of all three substances from the permanent clinical-need pathway for 503B facilities.

503A patient-specific compounding remains open for GLP-1 therapies subject to its own conditions, including the prohibition on compounding "essentially a copy" of a commercially available drug. 503B bulk pathways for semaglutide and tirzepatide are significantly constrained following the resolution of those shortages and the pending proposal. The two pathways have always operated under different legal frameworks — the proposal sharpens that distinction for these three molecules.

503A compounding occurs in state-licensed pharmacies (or by licensed physicians in some cases) pursuant to a valid, patient-specific prescription. It is primarily overseen by state boards of pharmacy, with federal conditions including the prohibition on compounding "essentially a copy" of a commercially available drug except under limited circumstances. Clinics and pharmacies must carefully document medical necessity and avoid marketing claims that position compounded versions as identical or interchangeable with FDA-approved drugs. FDA has previously issued warning letters addressing such claims.

503B compounding occurs in FDA-registered outsourcing facilities that may produce larger batches for office use without individual prescriptions, but must follow cGMP standards, register with FDA, and report products. For GLP-1 receptor agonists, the resolved shortages removed the primary temporary pathway that previously supported broader 503B activity for semaglutide and tirzepatide. The pending proposal addresses the remaining clinical-need route for bulk API use by 503B facilities.

The table below reflects the statutory structure and the April 2026 proposal. Final FDA action and state enforcement can alter practical availability — verify current shortage status and facility registration before placing any order.

Clinics should evaluate three primary dimensions: legal pathway availability and documentation requirements; operational needs (office-stock versus patient-specific fulfillment); and quality and chain-of-custody controls. No pathway eliminates residual risk — compounded products are not FDA-approved and lack the premarket review for safety, efficacy, and manufacturing consistency that applies to approved drugs.

Apply this checklist before placing any compounded GLP-1 order:

1. Confirm current shortage status for the specific molecule on the FDA drug shortage list. Status changes; verify at the time of each order, not once per quarter.
2. For any 503B source, verify active FDA registration, recent inspection history if available, and whether the facility is relying on a shortage pathway or another permitted basis.
3. For 503A sources, confirm state licensure for sterile compounding where applicable, receipt of a valid patient-specific prescription, and documentation supporting that the compounded product is not essentially a copy.
4. Require Certificates of Analysis (COA), sterility and endotoxin testing data, and validated cold-chain shipping records for every lot — not just on initial onboarding.
5. Assess state-level restrictions, corporate-practice-of-medicine rules that may affect how a med spa or clinic structures ownership and medical direction, and any payer or medical-board guidance on compounded GLP-1 use.

Clinics remain responsible for informed consent, adverse-event monitoring, and compliance with both federal and state requirements regardless of which pathway they use.

Retain the original prescription, clinical rationale supporting a patient-specific difference from the approved product, COAs for the finished preparation, shipping and storage records, and evidence of the pharmacy's state licensure and sterile-compounding authorization. Documentation is not a one-time onboarding task — it is a per-lot, per-patient obligation that must be maintained for the duration of the patient relationship and beyond.

The minimum documentation set for each 503A-sourced compounded GLP-1 order:

• Original patient-specific prescription with prescriber NPI and date
• Clinical rationale documenting why the compounded version is not essentially a copy (e.g., documented allergy to an excipient in the approved product, required dose not commercially available)
• Certificate of Analysis for the specific lot received, including potency, sterility, endotoxin, and pH results
• Pharmacy license verification — state licensure and sterile compounding authorization current at the time of dispensing
• Shipping and cold-chain records — temperature logs for transit, especially for refrigerated or frozen preparations
• Adverse event monitoring records — any patient-reported reactions documented and retained

FDA has issued warning letters to clinics and pharmacies that marketed compounded GLP-1s without adequate documentation of patient-specific need. The documentation burden is real and ongoing.

No. The FDA's April 2026 proposal is limited to semaglutide, tirzepatide, and liraglutide for 503B Bulks List purposes. Research-use-only (RUO) peptides operate under a separate regulatory framework and are not affected by this proposal. However, RUO materials must not be represented or used as clinical therapeutics — the regulatory separation between RUO research compounds and compounded clinical medications is not a technicality; it is a hard legal line.

RUO peptides available through MedClinic Partners — including BPC-157, TB-500, CJC-1295/Ipamorelin, and others — are USA-manufactured cGMP materials supplied exclusively to NPI-verified licensed providers for research purposes. They are not compounded medications and are not subject to the 503A/503B framework. Access the peptide catalog through the portal →

Treat the current period as one of heightened documentation and verification requirements. Verify shortage status in real time, require transparent quality data from any supplier, maintain clear separation between research materials and clinical compounding, and ensure medical directors and compliance personnel understand both the federal proposal and applicable state rules.

The absence of a final determination means operational decisions must remain flexible pending FDA's post-comment review. Clinics that build robust documentation practices now will be better positioned regardless of how the final rule lands.

If you are evaluating your current supply chain in light of this proposal, request portal access to discuss your practice's specific pathway needs with our compliance team.

For licensed medical providers only. This post reflects publicly available regulatory information as of August 20, 2026 and does not constitute legal or regulatory advice. Regulatory status can change; verify current FDA shortage listings and facility registration status before placing any order. Consult qualified legal counsel for advice specific to your practice.